Last, an important potential mechanism of action for R848-BPD therapy would be activation of cross-presenting DC populations, which capture tumor antigens and migrate to tumor-draining lymph nodes to activate tumor-specific CD8+ T cells. Here, CD8A is linked to neoplasm.